• Daniel Cuevas-Ramos, Paloma Almeda-Valdés, Clara E Meza-Arana, Griselda Brito-Córdova, Doris Georgina Ruiz-Gómez, Christian Razo, and Francisco J Gómez-Pérez.
• Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
• Gac Med Mex. 2017 Jan 1; 153 (Supl. 2): S51S59S51-S59.

ObjectiveWe evaluated the effect of sitagliptin in correction of symptomatic reactive hypoglycemia.MethodsRandomized, double blind, placebo-controlled clinical trial. Thirteen patients treated with sitagliptin and 15 with placebo, with mean age of 34.3 ± 10.6 years and body mass index of 24.6 ± 5.1 kg/m2, mostly women (n = 24, 85.7%), were evaluated.ResultsBasal glycemia was similar in placebo versus sitagliptin (92.3 ± 18.9 vs. 93.4 ± 17.3 mg/dl; p = 0.41) as was median and interquartile range of insulin (15.2 [8.8-43.7] vs. 14.7 µU/ml [7.0-39.0]; p = 0.44). Patients with sitagliptin recovered the first phase insulin secretion (FISP). This was related with higher glucose level at the end of the oral glucose tolerance test (79.5 [74.2-83.0] vs. 83.5 [81.2-89.7]; p = 0.003) with a similar insulin median level (13.0 [5.0-34.4] vs. 13.8 [4.8-30.6]; p = 0.32). Symptomatology was significantly lower under sitagliptin treatment (p < 0.0001).ConclusionsSitagliptin improved FISP and reduced post-prandial symptomatology. These results suggest a novel therapeutic option for patients with reactive hypoglycemia related with FISP.Copyright: © 2017 SecretarÍa de Salud

26 keywords...

hide…